Abterra Biosciences

Reimagining antibody discovery and sequencing.

[Abterra Biosciences @AbterraBio]

Our second free web app - ab2annotation - is LIVE!

Key features:
👉 CDR & Germline calling
👉 Developability issues like N glycans, odd Cys, oxidation sites, charge, and hydrophobicity throughout the variable region.

➡️ Try ab2annotation for free: https://t.co/ITWzS1mVNo

[Abterra Biosciences @AbterraBio]

Meet Stefano Bonissone, Abterra Biosciences' Chief Scientific Officer!

Read more about our company history in #antibodydiscovery and #antibodysequencing: https://t.co/dp6zJ2Pwo8

[Abterra Biosciences @AbterraBio]

The immune response to challenge is vast and complex, but our Alicanto multi-omic approach to immune profiling enables us to create a map of target-reactive #antibodies, and help our partners find the best molecules for their project.

https://t.co/yiTIJagR5W

[Abterra Biosciences @AbterraBio]

For immune repertoire sequencing, every clone matters!

We reviewed the benefit of replicates across several repertoire sequencing project types.

tl;dr
Replicates can increase the number of clones identified in your sample by 50% or more!

https://t.co/giAlfd7ie7

[Abterra Biosciences @AbterraBio]

How many clones did your antibody discovery campaign really deliver?

Diverse candidate sequences are key to your campaign's success. Read more about how Abterra Bio delivers diverse antibodies with Alicanto.

https://t.co/S5JbQ2PitX

#antibodydiscovery #antibodysequencing

[Abterra Biosciences @AbterraBio]

Wishing you a very happy holiday season and many scientific discoveries in the New Year! #uglysweater #antibodysequencing #antibodydiscovery

[Abterra Biosciences @AbterraBio]

Did you miss @necastellana presentation at PEGS Boston?

Learn about "Discovering Antibodies From Patient Serum After Vaccination and Infection with SARS-CoV2" from anywhere you stream YouTube.

https://t.co/KD093ErCG9

[Abterra Biosciences @AbterraBio]

Have you lost the #hybridoma for an important antibody? Dr. Burchill from the Univ of Colorado knows the feeling. Read more about how we used Valens to rescue an antibody used in his chronic liver disease research. #antibody #antibodysequencing

https://t.co/O9LNavKgDU

[Abterra Biosciences @AbterraBio]

Why you should pick NGS over Sanger for your hybridoma sequencing? At Abterra Bio, we use NGS for our high-throughput hybridoma sequencing workflow to save you time and money!
Read about the key differences between NGS vs Sanger here: https://t.co/gKh98zHQOL
#hybridoma #NGS

[Abterra Biosciences @AbterraBio]

Given the flexibility of our Reptor workflow, we have put together a blog post showing how Reptor can analyze and compare antibody repertoire across multiple species! Click below to read more!

#antibodysequencing #repertoire analysis #immuneprofiling

https://t.co/sjp1TI0R5p

[Abterra Biosciences @AbterraBio]

Are you interested in joining the Abterra team? We have openings! Click to see our career opportunities in Sales and Marketing. Apply today if you want to be part of our incredible, innovative, and fun team!
https://t.co/OIWQj2Qvc3

#careers #sequencing #salesandmarketing

[Abterra Biosciences @AbterraBio]

Every day, Abterra Bio is helping companies discover single-domain antibodies for research, diagnostic and therapeutic purposes using our proprietary Alicanto technology. Contact us!

#biotech #antibodies #pharma
Check out this interesting paper @ https://t.co/aa3PuAVjn0

[Abterra Biosciences @AbterraBio]

The Abterra Bio team would like to wish you and your family a wonderful holiday season. We hope to work with you again in 2022!

[Abterra Biosciences @AbterraBio]

With the use of NGS, our Reptor software was able to analyze the clone diversity during the hybridoma generation process, clone overlap across 3 bulk samples, and relatives of screened hits that can be used for hit expansion. Read our new blog post below!

https://t.co/oQLlM3Avd0

[Abterra Biosciences @AbterraBio]

Using our Valens de novo antibody sequencing technology, we were able to cover missing amino acids from a published anti-FLAG M2 antibody sequence. Click below to read more about our case study!

#antibody #sequencing #pharma #biotech
https://t.co/0hV9EuXTIp

[Abterra Biosciences @AbterraBio]

Congratulations to Matthew Burchill for winning a free Valens de novo sequencing project! We look forward to our collaboration with him and the University of Colorado - School of Medicine.

#antibody #sequencing

[UCSD CSE @ucsd_cse]

Meet @necastellana! The UCSD CSE graduate and CEO of @AbterraBio believed that computer science, in conjunction with other scientific fields, had a critical role to play in ameliorating the global health crisis.

Read her feature story : https://t.co/VRIn89DubG

[Abterra Biosciences @AbterraBio]

Don’t miss the chance to recover your lost hybridoma for free!! Sign up for our case study: https://t.co/mDkBVQlbSv
Read more on our de novo sequencing approach and how it can be used to solve your problem!
#biopharma #sequencing
https://t.co/i44JgwjxxI

[San Diego & Imperial SBDC Network @SDSBDCNetwork]

Check out some fresh news about how 2 use our free SBDC services to gain significant funding + other business tools. We're honored to be working w/ you, @AbterraBio, as you strive to revolutionize cancer treatment. Thank you of sharing @TheBrinkSbdc #SDAC https://t.co/AxYdp1GNOr

[Abterra Biosciences @AbterraBio]

Lost your hybridoma? We can help! We will be selecting one project to feature in a case study on our website and will de novo sequence your antibody for free!
A participant for the case study will be determined by lottery. Click the link to sign up!

https://t.co/NofhkwMWhj